Featured

Texas Secures $45 Million Settlement With Gilead Over Medicaid Kickback Claims

Texas Attorney General Ken Paxton (R) has secured a $45 million settlement with pharmaceutical manufacturer Gilead Sciences to resolve allegations that the company used improper incentives to influence prescriptions covered by Texas Medicaid.

The agreement follows a lawsuit filed by Paxton's office in October 2023 under the Texas Health Care Program Fraud Prevention Act.

The state alleges that Gilead offered medical providers benefits, including free nursing services and reimbursement support, to encourage prescriptions of its medications over competing drugs. According to the attorney general's office, some of those prescriptions were paid for through Medicaid, generating claims that Texas alleged were connected to the company's marketing practices.

Gilead agreed to pay $45 million to resolve the state's claims. The company denied Texas' fraud allegations and said it accepted the settlement to avoid the cost and distraction of prolonged litigation.

What did Paxton say about the settlement?

Paxton described the agreement as part of his office's efforts to protect public health care funds and deter pharmaceutical companies from using incentives that could influence prescribing decisions.

"Doctors ought to prescribe medication in accordance with what is in the best interest of the patient," said Paxton, warning that his office would continue pursuing companies accused of jeopardizing Texans' health or misusing taxpayer dollars.

Is Texas pursuing similar cases against other drugmakers?

The Gilead agreement follows a separate settlement with AstraZeneca announced in June 2026. Under that agreement, AstraZeneca agreed to pay nearly $34 million to resolve allegations involving free nursing services and reimbursement support provided to prescribers.

Paxton's office has also filed lawsuits against Eli Lilly and Sanofi-Aventis over alleged incentives provided to health care providers. Those actions are part of the state's broader efforts to pursue pharmaceutical companies over alleged violations involving Medicaid prescriptions.

Raeylee Barefield

Raeylee Barefield is a Legislative Correspondent based in Austin, Texas, specializing in state government and public policy. With one year of reporting under her belt, she covers legislative developments, committee hearings, and policy debates. She has been cited by Texas Politics and Big Energy for her coverage and analysis of legislative and regulatory issues. Her reporting typically focuses on Public policy, Stare government, environmental policy, and energy regulation. To contact her, please reach out at Raeylee@dnm.news

Recent Posts

Beth Van Duyne Accuses Democrats of 'Punching' Voters in the Face Over Border Policy

WASHINGTON — U.S. Representative Beth Van Duyne (R) warned that a change in Texas leadership…

7 hours ago

Beth Van Duyne Draws Red Line on Healthcare: 'I'm Going to Fight Them'

WASHINGTON — U.S. Representative Beth Van Duyne (R) says she is willing to work with…

7 hours ago

Christian Menefee Seeks to Expand Suicide Prevention in Texas Schools

U.S. Representative Christian Menefee (D) has introduced legislation aimed at expanding access to youth suicide…

8 hours ago

Democrats Miss the Call as the House Clears Sweeping Veterans’ Bill

The House of Representatives passed an expansive veterans’ benefits bill on Veterans Day by voice…

9 hours ago

House Freedom Caucus Urges GOP to Finish the Job

Although the majority of its members will not be returning to Congress next year, the…

10 hours ago

Brandon Gill Backs Jim Jordan to Lead GOP, Vows to Fight Democrat ‘Lunatics’

In lieu of a rough road back to a majority, Republicans are facing an uphill…

10 hours ago